glp-1 inventor How Lotte Bjerre Knudsen helped kick off the Age of Wegovy Bending the Cost Curve: Understanding

this effect was similar to that observed with insulin

Bimagrumab addresses a critical unmet need. Mark Pruzanski The advantage: While people on GLP-1 agonists tend to gain back any weight lost if they stop taking the meds, that might not be the case for bimagrumab 12 weeks after their last dose, the people in the 1,000-person phase 2 trial had yet to regain any weight

Injectable GLP-1 RAs come in disposable pen injection devices

MK-677 causes major hunger boost, can increase cortisol levels, may affect insulin response with chronic use, and provides more constant rather than pulsatile GH rise

A larger randomized placebo-controlled study investigating the effects of sulforaphane on schizophrenia is ongoing and is expected to end in July of 2019